2024-05-28 RXST looks bullishRXST has a pretty good EPS and Sale growth. Consolidate into a tight base and looks like ready to go higher.
Market insights
RxSight Unveils Light Adjustable Lens for Cataract SurgeryRxSight, Inc., ( NASDAQ:RXST ) a trailblazing ophthalmic medical device company, has set its sights on revolutionizing cataract surgery with the commercial launch of its latest innovation, the Light Adjustable Lens+™ (LAL+). This pioneering lens, alongside its predecessor the LAL®, promises to deliver unparalleled customized vision solutions to patients post-cataract surgery. As the company unveils its breakthrough technology at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, the stage is set for a transformative leap forward in the field of ophthalmology.
Empowering Vision with Precision:
The introduction of the LAL+ marks a significant milestone in RxSight's mission to provide tailored vision correction options for patients. With its modified aspheric anterior surface, designed to enhance depth of focus, the LAL+ represents a leap forward in precision and versatility. By offering patients a broader range of vision enhancement possibilities, RxSight ( NASDAQ:RXST ) empowers individuals to reclaim clarity and comfort in their daily lives.
Scientific Validation at ASCRS Annual Meeting:
At the ASCRS Annual Meeting in Boston, RxSight's Light Adjustable Lens system takes center stage, with a robust lineup of scientific presentations showcasing its efficacy and potential. From discussions on the benefits of arcuate incisions to assessments of binocular vision post-implantation, leading ophthalmologists share insights and findings that underscore the transformative impact of RxSight's innovative technology. With over 20 scientific papers and presentations scheduled, the ASCRS meeting serves as a platform for collaboration and knowledge exchange among industry experts.
Unveiling Future Possibilities:
As doctors and researchers converge at the RxSight( NASDAQ:RXST ) booth to share their experiences and insights, the excitement surrounding the potential of the LAL+ reaches new heights. From panel discussions on the value of adjustability to hands-on demonstrations of the Light Adjustable Lens system, attendees gain firsthand exposure to the future of cataract surgery. With each presentation and interaction, RxSight ( NASDAQ:RXST ) reaffirms its commitment to advancing patient care through cutting-edge technology and collaboration.
Breakout w/ no tighteningCould be a breakout that was breaking above resistance around the $40.60 area. Not really liking how it never had any meaningful tightening like it did earlier around May / July of this year. As usual trend is up so we attempt to go along with it. We'll leave it to probability and let it sort itself out in the end.
Risk managed by a stop-loss order & position sizing equal to 0.5% of the buying power allocated to swing trades. Depending on price action will manage profits by using the 10 ema or 20 ema (will update as time passes).
Bought @ $40.73
Stop @ 39.38
$RXST looking to head higher?Notes:
* Coming up on the right side of its base
* Volume increasing with price
* Two levels of resistance at which we can take partial profits.
Technicals:
Ticker: $RXST
Sector: Healthcare - Medical Devices
Relative Strength vs. Sector: 25.97
Relative Strength vs. SP500: 8.57
U/D Ratio: 1.7
Base Depth: 82.72%
Distance from breakout buy point: 1.65%
Volume -8.06% below its 15 day avg.
$RXST is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $18,06;
stop-loss — $15,92;
take-profit — $24.48,/MOC price.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas
